Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920711 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,822
- Enrollment target
NCT01920711: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01920711 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,822 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (525% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01920711, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,822 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
Primary Outcome
The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association \[NYHA\] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction \[LVEF\] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.
Interventions
- DRUG Valsartan
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,822 participants |
| Start Date | 2014-07-18 |
| Est. Completion | 2019-06-07 |
| Phase | Phase 3 |
What the finished NCT01920711 record still lists
NCT01920711 is an interventional study that assigns participants to a tested intervention. Its 4,822 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (525% higher).
The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.
NCT01920711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01920711 about?
NCT01920711 is a clinical study titled "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction". The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
What is the current status of trial NCT01920711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,822 participants. The study started on 2014-07-18. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT01920711?
The interventions under investigation include: Valsartan (DRUG), LCZ696 (DRUG).
Who is sponsoring clinical trial NCT01920711?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01920711's enrollment target sits among peer trials
4,822 53rd of 2000 higher than 1,948 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
- NCT06307652 · 4,800 participants · Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI